The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Self-citationCoussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
Cited by
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Self-citationSpector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Combinatorial chemoprevention of intestinal neoplasia
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000) · Nature Medicine · doi:10.1038/79534 · Cited by 493
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Xu, H., Aguilar, Z. P., Yang, L., Kuang, M., Duan, H., Xiong, Y., Wei, H., & Wang, A. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.076 · Cited by 381
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Lebeau, A., Deimling, D., Kaltz, C., Sendelhofert, A., Iff, A., Luthardt, B., Untch, M., & Löhrs, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.354 · Cited by 326
Trastuzumab in the Treatment of Breast Cancer
Hortobagyi, G. N. (2005) · New England Journal of Medicine · doi:10.1056/nejme058196 · Cited by 306
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference
Tan, W. B., Jiang, S., & Zhang, Y. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.018 · Cited by 295
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2.
Morrissey, T. K., Levi, A. D., Nuijens, A., Sliwkowski, M. X., & Bunge, R. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1431 · Cited by 270
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 259
Mechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer
Reese, D. M., & Slamon, D. J. (1997) · STEM CELLS · doi:10.1002/stem.150001 · Cited by 229
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213
Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206
Niwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187
Malphettes, L., Freyvert, Y., Chang, J., Liu, P., Chan, E., Miller, J. C., Zhou, Z., Nguyen, T., Tsai, C., Snowden, A. W., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22751 · Cited by 164
Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0448 · Cited by 125
Self-citationDiscafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112
Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domenech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascon, P., Rovira, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0147 · Cited by 104
Jäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
Herceptin: From the Bench to the Clinic
Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R. (2001) · Cancer Investigation · doi:10.1081/cnv-100000074 · Cited by 43
Kuwada, S. K., Scaife, C. L., Kuang, J., Li, X., Wong, R. F., Florell, S. R., Coffey, R. J., & Gray, P. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.11686 · Cited by 41
Metadata
- Authors
- Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 1993-07
- Volume
- 37
- Issue
- 4
- Pages
- 255-263
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2082117763
- Cited by
- 498
- References
- 59
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.